Kura Oncology to Present at TD Cowen Oncology Innovation Summit
Event summary
- Kura Oncology to participate in a virtual fireside chat at TD Cowen's Oncology Innovation Summit on May 26, 2026.
- Event scheduled for 1:30 p.m. ET / 10:30 a.m. PT.
- Webcast and replay available on Kura's Investor Relations page.
- Kura focuses on precision medicines for cancer, including KOMZIFTI™ (ziftomenib) for relapsed/refractory NPM1-mutated AML.
The big picture
Kura Oncology's participation in the TD Cowen Oncology Innovation Summit underscores its strategic focus on precision oncology. The event provides a platform to discuss advancements in menin inhibition and farnesyl transferase inhibition, key areas in the treatment of hematologic malignancies and solid tumors. Kura's FDA-approved KOMZIFTI™ (ziftomenib) positions it as a notable player in the precision medicine space, with potential implications for its market positioning and pipeline development.
What we're watching
- Pipeline Progress
- How Kura's advancements in menin and farnesyl transferase inhibition will impact its pipeline.
- Market Positioning
- Whether Kura can sustain its leadership in precision oncology treatments.
- Regulatory Dynamics
- The pace at which Kura can secure additional FDA approvals for its drug candidates.
Related topics